Sprint Bioscience: Misery loves company - Redeye

Redeye is disappointed to learn that Sprint Bioscience will receive back the NASH program from LG Chem. This setback constitutes the second previously out-licensed project that partners have returned to Sprint Bioscience within the last six to 12 months. We will adjust our estimates and reduce our valuation in the coming days.

Länk till analysen i sin helhet: https://www.redeye.se/research/913481/sprint-bioscience-misery-loves-company?utm_source=finwire&utm_medium=RSS